We See
New Ways To
A Healthier


We work relentlessly to save sight through transformative science, creating solutions to treat vision-threatening diseases, that improve quality of life and care for all involved.


Approximately 80 million Americans are affected by potentially blinding eye disease and this number is projected to double by 2030 based on an aging population and the increasing prevalence of diseases that can cause vision loss.
Our Proprietary Technologies
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. Our diversified portfolio is designed to treat vision-threatening diseases of the retina, optic nerve, and cornea, by either maintaining effective drug levels in ocular tissues for long periods of time, using innovative technologies such as injectable sustained-release formulations, or by curing diseases with gene therapies.
Our gene therapy APPROACH
Our sustained-release formulation technologies
Microparticle technology
Our sustained-release formulation technologies
Implant Technology
Based on our proprietary technologies, our R&D pipeline targets a range of chronic vision-threatening diseases, some of which have no viable treatment option.
GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy.
GB-401 is a first-in-class implant formulation containing a novel prodrug of timolol for the treatment of primary open angle glaucoma (POAG) designed for a twice-per-year intravitreal injection with a proprietary applicator.
GB-501 is an adeno-associated virus (AAV) gene therapy with Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to treat corneal clouding caused by Mucopolysaccharidosis Type 1 (MPS1), a lysosomal storage disorder.
GB-601 is being developed as a long-acting formulation of a novel cGMP analog to address hereditary retinal diseases like Retinitis Pigmentosa, a group of genetic disorders that involve a loss of cells in the retina.
GB-701 is being developed as a long-acting formulation of a potent factor B inhibitor targeting the complement cascade which plays a role in AMD.
What Drives Us

“We make bold moves for the benefit of patients.
We are curious, resilient and don’t give up easily.
We thrive on the diversity of opinions and beliefs.
Which values guide you through life?”

Fred Guerard, PharmD, CEO

“The power of science means nothing until you see the impact it can have on people’s lives. Our singular focus is to deliver transformative medicines for patients suffering from vision-threatening diseases, and we do it in partnership with them.”

Parisa Zamiri, MD, PhD, CMO
MORE THAN 10 Years of
Vibrant Vision

Since 2011, we have been dedicated to transformative science making healthy vision more accessible and manageable for patients with chronic vision-threatening eye diseases. Watch the video to learn about how it all started, what drives us, and what our vision for the future looks like.